Overview
Pharmacogenetic Study in Patients With Relapsing Forms of Multiple Sclerosis Who Developed ITP After Receiving Lemtrada
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2019-06-01
2019-06-01
Target enrollment:
35
35
Participant gender:
All
All
Summary
Primary Objective: To assess in a new cohort of patients pre-identified candidate single nucleotide polymorphism (SNPs) associated to the development of immune thrombocytopenic purpura (ITP) after LEMTRADA treatment in relapsing multiple sclerosis (RMS) patients.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Genzyme, a Sanofi CompanyTreatments:
Alemtuzumab
Criteria
Inclusion criteria :- Male and female adult patients who have been treated with LEMTRADA, as per label, with
development of immune thrombocytopenic purpura (ITP) subsequent to treatment. Patients
do not need to be currently on LEMTRADA treatment.
- Patients who have signed the study informed consent form (ICF).
Exclusion criteria:
- Not applicable
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.